A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)

Researchers are looking for new ways to treat people with a type of blood cancer called precursor B-cell Acute Lymphoblastic Leukemia (B-ALL) that is relapsed- the cancer has come back after treatment, or refractory - the current treatment has stopped working to slow or stop cancer growth. This study will have two parts. In the first part (dose escalation phase) the goal is to learn about the safety of a study treatment, MK-1045, and to find the best dose level of MK-1045 that is tolerated and may work to treat B-ALL. In the second part (Phase II) researchers want to learn how well MK-1045 wor

Trial Details

NCT ID
NCT05579132
Phase
PHASE1 / PHASE2
Sponsor
MSD R&D (China) Co., Ltd.
Status
RECRUITING
Cancer Type
Acute Lymphoblastic (ALL) Leukemia
Interventions
  • MK-1045
Locations (sample)
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Shijiazhuang, Hebei, China|38.04139,114.47861
  • Harbin, Heilongjiang, China|45.75,126.65
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • Adult participants must be age 18 or older
  • Pediatric participants must be at least 2 years old and less than 18 years old.
  • Diagnosis of precursor B-cell acute lymphoblastic leukemia (B-ALL) and have more than 5% blasts in the bone marrow by morphological assessment
  • Participants with Ph-negative B-ALL with any of the following refractory/relapse criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Lymphoblastic (ALL) Leukemia Trials on Trialify →